Skip to main content
Otsuka Holdings Co., Ltd. logo

Otsuka Holdings Co., Ltd. — Investor Relations & Filings

Ticker · 4578 ISIN · JP3188220002 T Manufacturing
Open in API
Filings indexed 88 across all filing types
Latest filing 2025-05-07 Major Shareholding Noti…
Country JP Japan
Listing T 4578

About Otsuka Holdings Co., Ltd.

https://www.otsuka.co.jp/en/

Otsuka Holdings Co., Ltd. is a global healthcare company dedicated to creating innovative products for better health worldwide. The company operates through two core segments: a Pharmaceutical business and a Nutraceutical business. The Pharmaceutical division focuses on the research, development, and commercialization of treatments for diseases, with key areas including central nervous system disorders, oncology, cardiovascular diseases, and infectious diseases. The Nutraceutical division provides products based on scientific evidence to support daily health maintenance and improvement. This segment includes a wide range of functional foods, nutritional supplements, functional beverages, and cosmeceuticals, with well-known brands such as POCARI SWEAT, Calorie Mate, and Nature Made.

Recent filings

Filing Released Lang Actions
臨時報告書
Major Shareholding Notification Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director. The filing reason explicitly states it is due to a change in a major shareholder ("主要株主に異動がありましたので"), citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. This structure and content—reporting changes in major shareholdings (crossing ownership thresholds)—perfectly matches the definition of a Major Shareholding Notification. In the provided schema, this corresponds to code MRQ.
2025-05-07 Japanese
訂正臨時報告書
M&A Activity Classification · 100% confidence The document is titled "訂正臨時報告書" (Correction Extraordinary Report) and explicitly states its filing purpose under the Financial Instruments and Exchange Act (金融商品取引法) as an '臨時報告書' (Extraordinary Report). The content details a significant corporate action: a subsidiary's capital participation in a newly established joint venture (Otsuka ICU Medical LLC), resulting in the new entity becoming a specified subsidiary (特定子会社) with a 60% voting stake. This type of report, filed outside of regular periodic filings to disclose material, non-routine events, corresponds to the Japanese equivalent of a significant event disclosure, which is best categorized as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) due to the M&A/JV nature. However, given the structure and the explicit mention of '臨時報告書' (Extraordinary Report) which often covers material events not covered by other specific codes (like 10-K, ER, DIV), and the fact that it is a disclosure of a major transaction (JV formation/acquisition of control), RNS (Regulatory Filings) is the most appropriate general category for non-standard, mandatory disclosures in this context, especially since 'TAR' (M&A Activity) is usually reserved for takeover bids/mergers, and this is a JV capital injection. Since the document is a full disclosure report, not an announcement *about* a report, the RPA rule does not apply. Given the nature of disclosing a major transaction via an Extraordinary Report, RNS is the best fit among the provided codes for a Japanese regulatory filing of this nature.
2025-05-02 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document title is "自己株券買付状況報告書（法24条の６第１項に基づくもの）" which translates to "Report on the Status of Treasury Stock Acquisition (Based on Article 24-6, Paragraph 1 of the Financial Instruments and Exchange Act)". This is a specific regulatory filing in Japan detailing the company's share repurchase activities during a defined reporting period (March 1, 2025, to March 31, 2025). This content directly relates to the company buying back or selling its own shares. Therefore, the most appropriate classification is 'Transaction in Own Shares' (POS).
2025-04-14 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being filed because resolutions were passed at the Annual General Meeting (AGM) held on March 28, 2025. Section 2 details the resolutions, specifically the election of 13 directors, along with the vote counts (For, Against, Abstain) and the resulting approval status. This content directly relates to the official results of a shareholder vote following a general meeting. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-04-01 Japanese
臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director ("関東財務局長"). The filing date is April 1, 2025. The content details the resolution by the Board of Directors on March 28, 2025, regarding the disposal of treasury stock (自己株式の処分) to directors and executives as part of a restricted stock compensation plan (譲渡制限付株式報酬制度). This type of filing, which reports a specific, material corporate action (like a stock issuance or disposal outside of regular capital changes) that requires immediate disclosure under Japanese financial regulations (specifically referencing the Financial Instruments and Exchange Act), aligns best with the category for general regulatory announcements or timely disclosures that don't fit a more specific category like 10-K or ER. In the provided schema, the closest fit for a mandatory, non-standard regulatory disclosure is 'Regulatory Filings' (RNS), as it is a specific regulatory report (企業内容等の開示に関する内閣府令 第五号の三様式) that is not an Annual Report (10-K), Interim Report (IR), or a simple announcement of a report (RPA).
2025-04-01 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly references '金融商品取引法第24条の４の２第１項' (Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type, as they do not contain the actual financial statements themselves. FY 2024
2025-03-31 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.